We will also include more ccRCC validation cohorts and assess the postoperative follow-up data for analyzing and validating the significance of the POLD1 protein as a possible prognostic marker of patient survival in the future. This evidence concerns the gene POLD1 and nonpapillary renal cell carcinoma.